Cobenfy is the first drug to treat the disease that targets the brain's cholinergic receptors


Washington: The US Food and Drug Administration has approved a new drug for adults with schizophrenia.
The drug, commonly known as Cobenfy, is the first drug to treat the disease that targets the brain's cholinergic receptors, rather than the dopamine receptors that are the traditional focus of treatment.
“Schizophrenia is the leading cause of disability worldwide,” said Dr. Tiffany Farshion in the Institute's Department of Neuroscience.
He stated the drug represents the first new approach to treating schizophrenia. It offers a new alternative to the antipsychotic drugs that have previously been prescribed to people with schizophrenia.
It is pertinent to note that schizophrenia is a severe, chronic mental illness that often impairs a person's quality of life.
Pakistan opens doors to global crypto firms with new licensing initiative
- 5 hours ago

Renowned Iranian singer Omid Jahan dies of heart attack during stage performance
- 4 hours ago

Family of three killed in GT Road crash near Gujar Khan
- 2 hours ago

Bottom 10: The spitting distance between Florida and Arizona State
- 13 hours ago
Resolution submitted in Punjab Assembly seeking ban on TikTok
- 3 hours ago

Is this the “sickest generation” in American history? Not even close.
- 3 hours ago
PDMA issues alert for 11th monsoon spell in Punjab
- 5 hours ago

Nova Launcher’s founder and sole developer has left
- 5 hours ago

Earthquake shocks Gilgit-Baltistan's Astore region
- 5 hours ago

193 killed in two separate boat accidents in DR Congo
- 4 hours ago

Rally Arcade Classics gets manual transmission option in latest update
- 13 hours ago

Let’s be honest about Charlie Kirk’s life — and death
- 12 hours ago